Analysts’ Viewpoint
Development of innovative delivery technologies and advancements in medical expertise are expected to fuel the peptide therapeutics market size. PEGylation is a popular trend in the peptide drug chemical structure, which improves pharmacologic properties by increasing half-life, reducing antigenicity and immunogenicity, and improving solubility.
Overcoming challenges of oral peptide delivery, such as formulating peptides with excipients, using absorption enhancers, targeting specific cells or tissues, and developing peptide-based prodrugs that are converted to active peptides after absorption are likely to drive peptide therapeutics market growth. The rise in interest in peptide-based therapeutic vaccines is also likely to further drive market progress. The market is predicted to remain a lucrative sector in the coming years and continue to experience healthy growth.
Peptide therapeutics are increasingly used in the treatment of cancer, metabolic disorders, and in hormonal therapy. The growth in peptide applications for diabetes, obesity, osteoarthritis, and osteoporosis is further projected to boost the industry. Advancement of sophisticated drug delivery methods, as well as surge in funding in this sector, are predicted to have a disruptive influence on the field of peptide-based medicine.
The development of oral peptide therapeutics, which offer several advantages over injectable peptide drugs, such as improved patient convenience and compliance, a lower risk of infection and other complications associated with injections, and the potential to reach a broader range of patients, is expected to offer lucrative opportunities for market expansion. Additionally, the development of cyclized peptides, which are more often generated due to their enhanced conformational stability, is projected to propel market statistics.
The development of oral peptide therapies, cyclized peptides, and other breakthroughs in the industry are likely to further act as market catalysts.
Rise in prevalence of chronic diseases is driving demand for new treatments and augmenting the peptide therapeutics market value. According to the Centers for Disease Control and Prevention (CDC), six in ten adults in the United States have at least one chronic disease, and four in ten have two or more. Cancer is the second leading cause of death worldwide, accounting for 9.9 million deaths in 2020, and the prevalence of diabetes in the US has increased from 8.0% in 2010 to 10.2% in 2020.
Peptide therapeutics offer numerous advantages over traditional small molecule and biologic therapies. A 2021 study found that semaglutide, a peptide therapeutic, was effective in reducing blood sugar levels and improving cardiovascular outcomes in type 2 diabetes patients. Peptide application in cancer treatment also provides promising opportunities for future growth in the peptide therapeutics market.
The peptide therapeutics market segmentation in terms of product type includes innovative, and generic. The innovative segment accounted for largest global peptide therapeutics industry share in 2022. Huge investments made by market players in research and development activities of innovative products is driving market dynamics. Large number of revenue- generating peptide drugs come under this category.
Based on application, the metabolic segment dominated the global market demand in 2022. Sedentary lifestyles, rapid rise in geriatric population, and increase in frequency of metabolic illnesses is influencing the growth to the segment. Because peptide therapies may be engineered to target specific receptors or enzymes involved in metabolic processes, they offer several benefits such as high specificity, minimal toxicity, and good tolerance.
The metabolic category is viewed as a highly profitable application by major pharmaceutical firms. The growing use of peptides to treat metabolic illnesses such as diabetes, obesity, osteoarthritis, and osteoporosis is likely to drive segment growth and fuel peptide therapeutics market opportunities.
The peptide therapeutics market analysis based on types of peptides includes native peptides, analog peptides, and heterologous peptides. The native peptides segment held significant share in 2022. Native peptides have become increasingly attractive for therapeutic development due to their improved safety, efficacy, and tolerability compared to synthetic peptides or other drug classes. Their inherent safety advantage is the major factor contributing to their projected dominance in the market.
Based on manufacturing type, the market is categorized into in-house, and CMO. The in-house segment dominated the global market in 2022. Cost-effectiveness, flexibility, confidentiality, and iterative synthesis approaches are key factors driving the segment. Researchers can customize peptide length, sequence, modifications, and purity to suit their research objectives.
As per the latest peptide therapeutics market forecast, North America dominated the global industry in 2022, ascribed to the presence of key drug manufacturers such as Novo Nordisk A/S., Eli Lilly and Company, and AstraZeneca, who are actively investing in research and development of novel therapies.
Asia Pacific holds a significant share of the global market. Rise in diabetes and cancer prevalence in countries such as China, India, and Japan, due to aging populations, and lifestyle & environmental changes are likely to drive market demand in the region.
Leading players in the global peptide therapeutics market have adopted strategies such as product portfolio expansion, and mergers & acquisition in order to increase market share.
Amgen, Inc., Sachem Holding AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Novartis AG, Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. are the prominent players in the market.
Key players have been profiled in the global peptide therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 | US$ 37.8 Bn |
| Forecast (Value) in 2031 | US$ 85.9 Bn |
| Growth Rate (CAGR) | 9.6% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It provides segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 37.8 Bn in 2022
It is projected to reach more than US$ 85.9 Bn by 2031
The CAGR is projected to be 9.6% from 2023 to 2031
Increase in prevalence of metabolic disorders and precise control over dosage
North America is projected to account for major share during the forecast period
Amgen, Inc., Sachem Holding AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Novartis AG, Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Peptide Therapeutics Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Peptide Therapeutics Market Analysis and Forecasts, 2023-2031
5. Key Insights
5.1. FDA-approved Peptide Therapeutics in 2022
5.2. Peptide Drugs Approved Since 2000, with their Targets and Indications
5.3. White Space Analysis
5.4. Porter's Analysis
5.5. Pipeline Analysis
5.6. Peptide Drugs Chemical Structure Trend Analysis
5.7. Separation Media Used for Peptide Drugs
5.8. COVID-19 Impact Analysis
6. Global Peptide Therapeutics Market Analysis and Forecasts, By Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product Type, 2023-2031
6.3.1. Innovative
6.3.2. Generic
6.4. Market Attractiveness By Product Type
7. Global Peptide Therapeutics Market Analysis and Forecasts, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2023-2031
7.3.1. Metabolic
7.3.2. Oncology
7.3.3. Gastrointestinal
7.3.4. Cardiovascular
7.3.5. Neurological
7.3.6. Others
7.4. Market Attractiveness By Application
8. Global Peptide Therapeutics Market Analysis and Forecasts, By Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Route of Administration, 2023-2031
8.3.1. Parenteral
8.3.2. Oral
8.3.3. Others
8.4. Market Attractiveness By Route of Administration
9. Global Peptide Therapeutics Market Analysis and Forecasts, By Types of Peptide
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Types of Peptide, 2023-2031
9.3.1. Native Peptides
9.3.2. Analog Peptides
9.3.3. Heterologous Peptides
9.4. Market Attractiveness By Types of Peptide
10. Global Peptide Therapeutics Market Analysis and Forecasts, By Technology
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By Technology, 2023-2031
10.3.1. Liquid Phase
10.3.2. Solid Phase
10.3.3. Hybrid
10.4. Market Attractiveness By Technology
11. Global Peptide Therapeutics Market Analysis and Forecasts, By Manufacturing Type
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast By Manufacturing Type, 2023-2031
11.3.1. In-house
11.3.2. CMO
11.4. Market Attractiveness By Manufacturing Type
12. Global Peptide Therapeutics Market Analysis and Forecasts, By Region
12.1. Key Findings
12.2. Market Value Forecast By Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness By Country/Region
13. North America Peptide Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product Type, 2023-2031
13.2.1. Innovative
13.2.2. Generic
13.3. Market Value Forecast By Application, 2023-2031
13.3.1. Metabolic
13.3.2. Oncology
13.3.3. Gastrointestinal
13.3.4. Cardiovascular
13.3.5. Neurological
13.3.6. Others
13.4. Market Value Forecast By Route of Administration, 2023-2031
13.4.1. Parenteral
13.4.2. Oral
13.4.3. Others
13.5. Market Value Forecast By Types of Peptide, 2023-2031
13.5.1. Native Peptides
13.5.2. Analog Peptides
13.5.3. Heterologous Peptides
13.6. Market Value Forecast By Technology, 2023-2031
13.6.1. Liquid Phase
13.6.2. Solid Phase
13.6.3. Hybrid
13.7. Market Value Forecast By Manufacturing Type, 2023-2031
13.7.1. In-house
13.7.2. CMO
13.8. Market Value Forecast By Country, 2023-2031
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Product Type
13.9.2. By Application
13.9.3. By Route of Administration
13.9.4. By Types of Peptide
13.9.5. By Technology
13.9.6. By Manufacturing Type
13.9.7. By Country
14. Europe Peptide Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product Type, 2023-2031
14.2.1. Innovative
14.2.2. Generic
14.3. Market Value Forecast By Application, 2023-2031
14.3.1. Metabolic
14.3.2. Oncology
14.3.3. Gastrointestinal
14.3.4. Cardiovascular
14.3.5. Neurological
14.3.6. Others
14.4. Market Value Forecast By Route of Administration, 2023-2031
14.4.1. Parenteral
14.4.2. Oral
14.4.3. Others
14.5. Market Value Forecast By Types of Peptide, 2023-2031
14.5.1. Native Peptides
14.5.2. Analog Peptides
14.5.3. Heterologous Peptides
14.6. Market Value Forecast By Technology, 2023-2031
14.6.1. Liquid Phase
14.6.2. Solid Phase
14.6.3. Hybrid
14.7. Market Value Forecast By Manufacturing Type, 2023-2031
14.7.1. In-house
14.7.2. CMO
14.8. Market Value Forecast By Country, 2023-2031
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Spain
14.8.5. Italy
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Product Type
14.9.2. By Application
14.9.3. By Route of Administration
14.9.4. By Types of Peptide
14.9.5. By Technology
14.9.6. By Manufacturing Type
14.9.7. By Country
15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Product Type, 2023-2031
15.2.1. Innovative
15.2.2. Generic
15.3. Market Value Forecast By Application, 2023-2031
15.3.1. Metabolic
15.3.2. Oncology
15.3.3. Gastrointestinal
15.3.4. Cardiovascular
15.3.5. Neurological
15.3.6. Others
15.4. Market Value Forecast By Route of Administration, 2023-2031
15.4.1. Parenteral
15.4.2. Oral
15.4.3. Others
15.5. Market Value Forecast By Types of Peptide, 2023-2031
15.5.1. Native Peptides
15.5.2. Analog Peptides
15.5.3. Heterologous Peptides
15.6. Market Value Forecast By Technology, 2023-2031
15.6.1. Liquid Phase
15.6.2. Solid Phase
15.6.3. Hybrid
15.7. Market Value Forecast By Manufacturing Type, 2023-2031
15.7.1. In-house
15.7.2. CMO
15.8. Market Value Forecast By Country, 2023-2031
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Product Type
15.9.2. By Application
15.9.3. By Route of Administration
15.9.4. By Types of Peptide
15.9.5. By Technology
15.9.6. By Manufacturing Type
15.9.7. By Country
16. Latin America Peptide Therapeutics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Product Type, 2023-2031
16.2.1. Innovative
16.2.2. Generic
16.3. Market Value Forecast By Application, 2023-2031
16.3.1. Metabolic
16.3.2. Oncology
16.3.3. Gastrointestinal
16.3.4. Cardiovascular
16.3.5. Neurological
16.3.6. Others
16.4. Market Value Forecast By Route of Administration, 2023-2031
16.4.1. Parenteral
16.4.2. Oral
16.4.3. Others
16.5. Market Value Forecast By Types of Peptide, 2023-2031
16.5.1. Native Peptides
16.5.2. Analog Peptides
16.5.3. Heterologous Peptides
16.6. Market Value Forecast By Technology, 2023-2031
16.6.1. Liquid Phase
16.6.2. Solid Phase
16.6.3. Hybrid
16.7. Market Value Forecast By Manufacturing Type, 2023-2031
16.7.1. In-house
16.7.2. CMO
16.8. Market Value Forecast By Country, 2023-2031
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Product Type
16.9.2. By Application
16.9.3. By Route of Administration
16.9.4. By Types of Peptide
16.9.5. By Technology
16.9.6. By Manufacturing Type
16.9.7. By Country
17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast By Product Type, 2023-2031
17.2.1. Innovative
17.2.2. Generic
17.3. Market Value Forecast By Application, 2023-2031
17.3.1. Metabolic
17.3.2. Oncology
17.3.3. Gastrointestinal
17.3.4. Cardiovascular
17.3.5. Neurological
17.3.6. Others
17.4. Market Value Forecast By Route of Administration, 2023-2031
17.4.1. Parenteral
17.4.2. Oral
17.4.3. Others
17.5. Market Value Forecast By Types of Peptide, 2023-2031
17.5.1. Native Peptides
17.5.2. Analog Peptides
17.5.3. Heterologous Peptides
17.6. Market Value Forecast By Technology, 2023-2031
17.6.1. Liquid Phase
17.6.2. Solid Phase
17.6.3. Hybrid
17.7. Market Value Forecast By Manufacturing Type, 2023-2031
17.7.1. In-house
17.7.2. CMO
17.8. Market Value Forecast By Country, 2023-2031
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Product Type
17.9.2. By Application
17.9.3. By Route of Administration
17.9.4. By Types of Peptide
17.9.5. By Technology
17.9.6. By Manufacturing Type
17.9.7. By Country
18. Competition Landscape
18.1. Market Player - Competition Matrix (By Tier and Size of companies)
18.2. Market Share Analysis By Company (2022)
18.3. Company Profiles
18.3.1. Amgen, Inc.
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. Financial Overview
18.3.1.4. SWOT Analysis
18.3.1.5. Strategic Overview
18.3.2. Sachem Holding AG
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. Financial Overview
18.3.2.4. SWOT Analysis
18.3.2.5. Strategic Overview
18.3.3. Eli Lilly and Company
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. Financial Overview
18.3.3.4. SWOT Analysis
18.3.3.5. Strategic Overview
18.3.4. F. Hoffmann-La Roche Ltd.
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. Financial Overview
18.3.4.4. SWOT Analysis
18.3.4.5. Strategic Overview
18.3.5. GlaxoSmithKline plc
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. Financial Overview
18.3.5.4. SWOT Analysis
18.3.5.5. Strategic Overview
18.3.6. Novartis AG
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. Financial Overview
18.3.6.4. SWOT Analysis
18.3.6.5. Strategic Overview
18.3.7. Pfizer, Inc.
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. Financial Overview
18.3.7.4. SWOT Analysis
18.3.7.5. Strategic Overview
18.3.8. Sanofi
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. Financial Overview
18.3.8.4. SWOT Analysis
18.3.8.5. Strategic Overview
18.3.9. Takeda Pharmaceutical Company Limited
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. Financial Overview
18.3.9.4. SWOT Analysis
18.3.9.5. Strategic Overview
18.3.10. Teva Pharmaceutical Industries Ltd.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. Financial Overview
18.3.10.4. SWOT Analysis
18.3.10.5. Strategic Overview
List of Tables
Table 01: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 02: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 03: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
Table 04: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
Table 05: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
Table 06: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, Manufacturing Type, 2023-2031
Table 07: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Region, 2023-2031
Table 08: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
Table 09: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 10: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
Table 11: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 12: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
Table 13: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
Table 14: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
Table 15: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
Table 16: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 17: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
Table 18: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 19: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
Table 20: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
Table 21: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
Table 22: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
Table 23: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 24: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
Table 25: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 26: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
Table 27: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
Table 28: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
Table 29: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
Table 30: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 31: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
Table 32: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 33: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Type of Peptide, 2023-2031
Table 34: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
Table 35: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
Table 36: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 37: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
Table 38: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
Table 39: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
Table 40: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Type of Peptide, 2023-2031
Table 41: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
Table 42: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
Table 43: Global Peptide Therapeutics Market: Company Share Analysis, 2022
List of Figures
Figure 01: Global Peptide Therapeutics Market Size, by Application, 2022
Figure 02: Peptide Therapeutics Market share (%), by Application, 2022
Figure 03: Peptide Therapeutics Market Size, by Route of Administration, 2022
Figure 04: Peptide Therapeutics Market share (%), by Route of Administration, 2022
Figure 05: Peptide Therapeutics Market Size, by Product Type, 2022
Figure 06: Peptide Therapeutics Market share (%), by Product Type, 2022
Figure 07: Peptide Therapeutics Market Size, by Types of Peptide, 2022
Figure 08: Peptide Therapeutics Market share (%), by Types of Peptide, 2022
Figure 09: Peptide Therapeutics Market Size, by Technology, 2022
Figure 10: Peptide Therapeutics Market share (%), by Technology, 2022
Figure 11: Peptide Therapeutics Market Size, by Manufacturing Type, 2022
Figure 12: Peptide Therapeutics Market share (%), by Manufacturing Type, 2022
Figure 13: Global Peptide Therapeutics Market, By Region (2022 and 2031)
Figure 14: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, 2023-2031
Figure 16: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022
Figure 15: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 17: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2031
Figure 18: Global Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 19: Global Peptide Therapeutics Market Value (US$ Mn), by Innovative, 2023-2031
Figure 20: Global Peptide Therapeutics Market Value Share Analysis, by Innovative, 2022 and 2031
Figure 21: Global Peptide Therapeutics Market Value (US$ Mn), by Generic, 2023-2031
Figure 22: Global Peptide Therapeutics Market Value Share Analysis, by Generic, 2022 and 2031
Figure 23: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 24: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2022
Figure 25: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2031
Figure 26: Global Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
Figure 27: Global Peptide Therapeutics Market Value (US$ Mn), by Metabolic, 2023-2031
Figure 28: Global Peptide Therapeutics Market Value Share Analysis, by Metabolic, 2022 and 2031
Figure 29: Global Peptide Therapeutics Market Value (US$ Mn), by Oncology, 2023-2031
Figure 30: Global Peptide Therapeutics Market Value Share Analysis, by Oncology, 2022 and 2031
Figure 31: Global Peptide Therapeutics Market Value (US$ Mn), by Gastrointestinal, 2023-2031
Figure 32: Global Peptide Therapeutics Market Value Share Analysis, by Gastrointestinal, 2022 and 2031
Figure 33: Global Peptide Therapeutics Market Value (US$ Mn), by Cardiovascular, 2023-2031
Figure 34: Global Peptide Therapeutics Market Value Share Analysis, by Cardiovascular, 2022 and 2031
Figure 35: Global Peptide Therapeutics Market Value (US$ Mn), by Neurological, 2023-2031
Figure 36: Global Peptide Therapeutics Market Value Share Analysis, by Neurological, 2022 and 2031
Figure 37: Global Peptide Therapeutics Market Value (US$ Mn), by Others, 2023-2031
Figure 38: Global Peptide Therapeutics Market Value Share Analysis, by Others, 2022 and 2031
Figure 39: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2022 and 2031
Figure 40: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2022
Figure 41: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2031
Figure 42: Global Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration Type, 2023-2031
Figure 43: Global Peptide Therapeutics Market Value (US$ Mn), by Parenteral, 2023-2031
Figure 44: Global Peptide Therapeutics Market Value Share Analysis, by Parenteral, 2022 and 2031
Figure 45: Global Peptide Therapeutics Market Value (US$ Mn), by Oral, 2023-2031
Figure 46: Global Peptide Therapeutics Market Value Share Analysis, by Oral, 2022 and 2031
Figure 47: Global Peptide Therapeutics Market Value (US$ Mn), by Others, 2023-2031
Figure 48: Global Peptide Therapeutics Market Value Share Analysis, by Others, 2022 and 2031
Figure 49: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2022 and 2031
Figure 50: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2022
Figure 51: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2031
Figure 52: Global Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide Type, 2023-2031
Figure 53: Global Peptide Therapeutics Market Value (US$ Mn), by Native Peptides, 2023-2031
Figure 54: Global Peptide Therapeutics Market Value Share Analysis, by Native Peptides, 2022 and 2031
Figure 55: Global Peptide Therapeutics Market Value (US$ Mn), by Analog Peptides, 2023-2031
Figure 56: Global Peptide Therapeutics Market Value Share Analysis, by Analog Peptides, 2022 and 2031
Figure 57: Global Peptide Therapeutics Market Value (US$ Mn), by Heterologous Peptides, 2023-2031
Figure 58: Global Peptide Therapeutics Market Value Share Analysis, by Heterologous Peptides, 2022 and 2031
Figure 59: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2022 and 2031
Figure 60: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2022
Figure 61: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2031
Figure 62: Global Peptide Therapeutics Market Attractiveness Analysis, by Technology Type, 2023-2031
Figure 63: Global Peptide Therapeutics Market Value (US$ Mn), by Liquid Phase, 2023-2031
Figure 64: Global Peptide Therapeutics Market Value Share Analysis, by Liquid Phase, 2022 and 2031
Figure 65: Global Peptide Therapeutics Market Value (US$ Mn), by Solid Phase, 2023-2031
Figure 66: Global Peptide Therapeutics Market Value Share Analysis, by Solid Phase, 2022 and 2031
Figure 67: Global Peptide Therapeutics Market Value (US$ Mn), by Hybrid, 2023-2031
Figure 68: Global Peptide Therapeutics Market Value Share Analysis, by Hybrid, 2022 and 2031
Figure 69: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type, 2022 and 2031
Figure 70: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type, 2022
Figure 71: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type, 2031
Figure 72: Global Peptide Therapeutics Market Attractiveness Analysis, Manufacturing Type, 2023-2031
Figure 73: Global Peptide Therapeutics Market Value (US$ Mn), by In-house, 2023-2031
Figure 74: Global Peptide Therapeutics Market Value Share Analysis, by In-house, 2022 and 2031
Figure 75: Global Peptide Therapeutics Market Value (US$ Mn), by CMO, 2023-2031
Figure 76: Global Peptide Therapeutics Market Value Share Analysis, by CMO, 2022 and 2031
Figure 77: Global Peptide Therapeutics Market Value Share Analysis, by Region, 2022 and 2031
Figure 78: Global Peptide Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
Figure 79: North America Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
Figure 80: North America Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 81: North America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 82: North America Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 83: North America Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
Figure 84: North America Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 85: North America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 86: North America Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 87: North America Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 88: North America Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031
Figure 89: North America Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031
Figure 90: North America Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
Figure 91: North America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
Figure 92: North America Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
Figure 93: North America Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
Figure 94: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
Figure 95: Europe Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 96: Europe Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 97: Europe Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 98: Europe Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
Figure 99: Europe Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 100: Europe Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 101: Europe Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 102: Europe Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 103: Europe Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031
Figure 104: Europe Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031
Figure 105: Europe Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
Figure 106: Europe Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
Figure 107: Europe Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
Figure 108: Europe Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
Figure 109: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
Figure 110: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 111: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 112: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 113: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
Figure 114: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 115: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 116: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 117: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 118: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031
Figure 119: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031
Figure 120: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
Figure 121: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
Figure 122: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
Figure 123: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
Figure 124: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
Figure 125: Latin America Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 126: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 127: Latin America Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 128: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
Figure 129: Latin America Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 130: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 131: Latin America Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 132: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 133: Latin America Peptide Therapeutics Market Value Share Analysis, by Type of Peptide, 2022 and 2031
Figure 134: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Type of Peptide, 2023-2031
Figure 135: Latin America Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
Figure 136: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
Figure 137: Latin America Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
Figure 138: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
Figure 139: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
Figure 140: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 141: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 142: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
Figure 143: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
Figure 144: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 145: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 146: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 147: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 148: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Type of Peptide, 2022 and 2031
Figure 149: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Type of Peptide, 2023-2031
Figure 150: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
Figure 151: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
Figure 152: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
Figure 153: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
Figure 154: Global Peptide Therapeutics Market: Company Share Analysis, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Peptide Therapeutics Market
